FindTrial
Sign In

INCB7839

DRUG2 trials

Sponsors

Masonic Cancer Center, University of Minnesota, Pediatric Brain Tumor Consortium

Conditions

Anaplastic AstrocytomaAnaplastic OligodendrogliomaCNS Primary Tumor, NOS (Malignant Glioma)DIPGDiffuse Large B Cell Non-Hodgkin LymphomaGlioblastoma MultiformeHigh-grade Astrocytoma NOS

Phase 1

ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL
CompletedNCT02141451
Masonic Cancer Center, University of MinnesotaDiffuse Large B Cell Non-Hodgkin Lymphoma
Start: 2014-05-31End: 2019-06-30Updated: 2020-02-19
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
CompletedNCT04295759
Pediatric Brain Tumor ConsortiumAnaplastic Astrocytoma, Anaplastic Oligodendroglioma, CNS Primary Tumor, NOS (Malignant Glioma) +3
Start: 2020-07-27End: 2024-12-01Updated: 2026-01-05

Related Papers

CNSC-02. PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC)-056: A PHASE 1 STUDY OF THE ADAM-10 INHIBITOR, INCB007839, IN CHILDREN WITH RECURRENT/PROGRESSIVE HIGH-GRADE GLIOMAS TO TARGET MICROENVIRONMENTAL NEUROLOGIN-3
Neuro-Oncology2024-06-183 citations